Menu Breaking news sponsored byCurrently, Abbott Laboratories (NYSE:ABT) has a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for 2 months.The company is one of 162 companies within the Health Care Equipment & Supplies GICS industry group, which is in turn part of the 782 company GICS Health Care sector. ABT has a market value of $95.4 billion which is in the top decile in its industry group The ranking for ABT by Portfolio Grader places it 43 among the 162 companies in this industry group, placing it in the top half.  Portfolio Grader currently ranks the Health Care sector number 9 among the 12 sectors in its universe putting it in the bottom quartile of all the GICS sectors. The Health Care Equipment & Supplies industry group is ranked 38 among the 69 industry groups within the GICS sectors, placing it below-average in terms of the Navellier scoring system.Abbott Laboratories has received above-average scores in 2 of the 8 fundamental areas evaluated by Portfolio Grader and average or below-average grades in 6 of the areas used in the ranking of company stocks.The company's operational scores provide mixed results with a ranking for sales growth that is well above the industry average but rankings for operating margin and earnings growth are below average. Scores for visibility of earnings are mixed, with rankings for earnings surprises and earnings revisions that are worse than average, while the score for earnings momentum is much better than average. ABT's scores for return on equity and cash flow are worse than its industry group average. These fundamental scores give Abbott Laboratories a position in the top half of the industry group. The Navellier Proprietary Quantitative Score is used by Portfolio Grader to gauge ABT's shares from the aspect of risk/reward. This exclusive scoring methodology assesses the relative value of ABT's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Considering this risk/reward calculation, the company currently scores above-average in its industry group compared to its peers.Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'.  Explore the tool here.Commentary provided by UpTick Data Technologies.Article printed from InvestorPlace Media, https://investorplace.com/2017/11/high-level-earnings-momentum-keep-abbott-laboratories-abt-a-buy/.©2017 InvestorPlace Media, LLC

								About Us							
							  ·  													
								Press Center							
							  ·  													
								Resources							
							  ·  													
								Advisory Services							
							  ·  													
								Free Newsletters							
							  ·  													
								Free Reports							
							  ·  													
								Contact Us							
							  ·  													
								Advertise With Us							
							  ·  													
								Employment							
							  ·  													
								Privacy							
							  ·  													
								Terms and Conditions							
							  ·  													
								Disclosures and Disclaimers							
							  ·  													
								Media Sites							


								RSS							
							  ·  													
								Sitemap							

More On InvestorPlace:
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright © 2017 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.